Gene study aims to unlock secrets of progressive lung disease
NCT ID NCT07580053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how inherited factors influence the speed of lung scarring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors predict how lung fibrosis will progress based on a patient's genes, leading to more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health, and results may not apply to all patients with lung fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Francesco Amati
Rozzano, Italy, 20089, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can a new daily pill slow lung scarring in IPF?
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases